Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dexcom (DXCM)

DexCom: Executive Chairman Kevin Sayer returns from leave effective March 2, 2026

Neutral Impact 3 of 5 leadership Written later

DexCom's Executive Chairman Kevin Sayer returned from a temporary leave of absence effective March 2, 2026, resuming his duties, and Lead Independent Director Mark Foletta resumed his duties as well. Under a letter agreement dated February 27, 2026, Sayer receives an annual base salary of $610,000 and restricted stock units with a fair value of $2,350,000 that vest in full on March 8, 2027.

Key points

  • Sayer took a temporary leave of absence effective September 14, 2025, and returned March 2, 2026
  • Annual base salary of $610,000 under the letter agreement dated February 27, 2026
  • Restricted stock units with a fair value of $2,350,000, vesting in full on March 8, 2027, subject to continued service
  • Sayer is no longer eligible for the Amended and Restated Severance & Change in Control Plan as an executive officer

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECMar 2, 2026, 4:15 PM ET
Accession number0001093557-26-000038

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 02, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.